Literature DB >> 20413807

Propranolol treatment for a giant infantile brain cavernoma.

Maria Moschovi, George A Alexiou, Kalliopi Stefanaki, Natalia Tourkantoni, Neofytos Prodromou.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20413807     DOI： 10.1177/0883073810363917

Source DB:  PubMed          Journal:  J Child Neurol        ISSN： 0883-0738            Impact factor:   1.987


× No keyword cloud information.
  8 in total

1.  Radiological features of childhood giant cavernous malformations.

Authors:  Burce Ozgen; Efsun Senocak; Kader K Oguz; Figen Soylemezoglu; Nejat Akalan
Journal:  Neuroradiology       Date:  2010-11-03       Impact factor: 2.804

2.  A 5-year outcome of propranolol for the treatment of paediatric intracranial cavernoma: case report and a review of the literature.

Authors:  Jakov Tiefenbach; Jay J Park; Chandrasekaran Kaliaperumal
Journal:  Childs Nerv Syst       Date:  2022-07-14       Impact factor: 1.532

3.  Calm the raging hormone - A new therapeutic strategy involving progesterone-signaling for hemorrhagic CCMs.

Authors:  Jun Zhang; Johnathan S Abou-Fadel
Journal:  Vessel Plus       Date:  2021-07-05

Review 4.  Cerebral Cavernous Malformation Pathogenesis: Investigating Lesion Formation and Progression with Animal Models.

Authors:  Chelsea M Phillips; Svetlana M Stamatovic; Richard F Keep; Anuska V Andjelkovic
Journal:  Int J Mol Sci       Date:  2022-04-30       Impact factor: 6.208

5.  Strategy for identifying repurposed drugs for the treatment of cerebral cavernous malformation.

Authors:  Christopher C Gibson; Weiquan Zhu; Chadwick T Davis; Jay A Bowman-Kirigin; Aubrey C Chan; Jing Ling; Ashley E Walker; Luca Goitre; Simona Delle Monache; Saverio Francesco Retta; Yan-Ting E Shiu; Allie H Grossmann; Kirk R Thomas; Anthony J Donato; Lisa A Lesniewski; Kevin J Whitehead; Dean Y Li
Journal:  Circulation       Date:  2014-12-08       Impact factor: 29.690

Review 6.  Initiation and use of propranolol for infantile hemangioma: report of a consensus conference.

Authors:  Beth A Drolet; Peter C Frommelt; Sarah L Chamlin; Anita Haggstrom; Nancy M Bauman; Yvonne E Chiu; Robert H Chun; Maria C Garzon; Kristen E Holland; Leonardo Liberman; Susan MacLellan-Tobert; Anthony J Mancini; Denise Metry; Katherine B Puttgen; Marcia Seefeldt; Robert Sidbury; Kendra M Ward; Francine Blei; Eulalia Baselga; Laura Cassidy; David H Darrow; Shawna Joachim; Eun-Kyung M Kwon; Kari Martin; Jonathan Perkins; Dawn H Siegel; Robert J Boucek; Ilona J Frieden
Journal:  Pediatrics       Date:  2012-12-24       Impact factor: 7.124

7.  Propranolol for familial cerebral cavernous malformation (Treat_CCM): study protocol for a randomized controlled pilot trial.

Authors:  Silvia Lanfranconi; Elisa Scola; Giulio Andrea Bertani; Barbara Zarino; Roberto Pallini; Giorgio d'Alessandris; Emanuela Mazzon; Silvia Marino; Maria Rita Carriero; Emma Scelzo; Giuseppe Faragò; Marco Castori; Carmela Fusco; Antonio Petracca; Leonardo d'Agruma; Laura Tassi; Piergiorgio d'Orio; Maria Grazia Lampugnani; Enrico Bjorn Nicolis; Antonella Vasamì; Deborah Novelli; Valter Torri; Jennifer Marie Theresia Anna Meessen; Rustam Al-Shahi Salman; Elisabetta Dejana; Roberto Latini
Journal:  Trials       Date:  2020-05-12       Impact factor: 2.279

8.  Systematic pharmacological screens uncover novel pathways involved in cerebral cavernous malformations.

Authors:  Cécile Otten; Jessica Knox; Gwénola Boulday; Mathias Eymery; Marta Haniszewski; Martin Neuenschwander; Silke Radetzki; Ingo Vogt; Kristina Hähn; Coralie De Luca; Cécile Cardoso; Sabri Hamad; Carla Igual Gil; Peter Roy; Corinne Albiges-Rizo; Eva Faurobert; Jens P von Kries; Mónica Campillos; Elisabeth Tournier-Lasserve; W Brent Derry; Salim Abdelilah-Seyfried
Journal:  EMBO Mol Med       Date:  2018-10       Impact factor: 12.137
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.